1. Home
  2. FCAP vs STTK Comparison

FCAP vs STTK Comparison

Compare FCAP & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Capital Inc.

FCAP

First Capital Inc.

N/A

Current Price

$48.15

Market Cap

125.9M

Sector

Finance

ML Signal

N/A

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$3.06

Market Cap

119.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FCAP
STTK
Founded
1891
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
125.9M
119.0M
IPO Year
1999
2020

Fundamental Metrics

Financial Performance
Metric
FCAP
STTK
Price
$48.15
$3.06
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$4.00
AVG Volume (30 Days)
4.0K
224.7K
Earning Date
01-23-2026
11-06-2025
Dividend Yield
2.44%
N/A
EPS Growth
25.19
N/A
EPS
4.41
N/A
Revenue
$47,323,000.00
$1,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$11.52
N/A
Revenue Growth
15.22
N/A
52 Week Low
$28.50
$0.69
52 Week High
$53.85
$3.12

Technical Indicators

Market Signals
Indicator
FCAP
STTK
Relative Strength Index (RSI) 69.75 79.66
Support Level $47.48 $1.93
Resistance Level $50.95 $2.18
Average True Range (ATR) 0.99 0.20
MACD 0.37 0.12
Stochastic Oscillator 97.55 98.42

Price Performance

Historical Comparison
FCAP
STTK

About FCAP First Capital Inc.

First Capital Inc is the financial holding company of First Harrison Bank. Through its subsidiary, it operates as a federally-chartered savings bank that provides banking services to individuals and business customers across locations in America. The bank offers various loans which include residential loans, construction loans, commercial real estate loans and commercial business loans. It also provides consumer loans such as home equity and second mortgage loans, and automobile and truck loans.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: